+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
E

Actively Recruiting

Researchers are studying the effects of a yoga-based cardiac rehabilitation program compared to an educational package for patients recovering from heart failure. The goal is to see if yoga classes can effectively support heart health and improve recovery compared to health education. This randomized controlled clinical trial focuses on patients with heart failure and reduced ejection fraction classified as NYHA class II or III. Participants are divided into two groups one receives a yoga-based rehabilitation program called Yoga-CaRe, which includes 20 sessions over three months along with long-term care and follow-up. The other group receives enhanced standard care through three health education sessions spread over the same period. Both interventions aim to improve heart health and quality of life. During the study, participants attend scheduled sessions and are monitored over time. Researchers assess major adverse cardiovascular events over a median follow-up of one year and evaluate heart failure-specific quality of life and physical function, such as the six-minute walk test, at three months. Additional measures include general quality of life, self-rated health, tobacco cessation, frailty, caregiver well-being, and healthcare costs. This study is led by the Centre for Chronic Disease Control in India and follows participants for up to one year.

Age: 18Years +All GendersPhase Not Applicable
16 locations